Inov8 Science, the wholly owned subsidiary of the AIM listed company Mid-States plc, has commissioned trials at several UK NHS hospitals as well as overseas hospitals, which have shown the effectiveness of the AD (air disinfection) technology against most microoganisms responsible for Healthcare Associated Infections (HCAI).
Inov8 said its AD system helps to prevent the airborne spread of a wide range of viruses, bacteria and fungi and provides continuous air disinfection with hydroxyl radicals at levels that mimic atmospheric concentrations which are harmless to humans but effective against bacteria and viruses.
Inov8 claims the system is already in use in clinics and hospitals throughout the world and the company continues to expand internationally through the appointment of specialist distributors.
Inov8 chief scientific officer Abdel Ezbiri said the evidence from the Royal Free Hospital clearly demonstrates that the AD can help to reduce environmental surface TVCs and MRSA by up 22% and 83% respectively.
"In the cases of the Royal Worcester Hospital and the Redditch Alexandra Hospital, the AD not only helped to reduce environmental air TVCs, but it also showed a good correlation between the TVC curve and patients’ infection rate curve for the same period," Ezbiri said.